BACKGROUND/AIMS: CD10 (CALLA) has recently been reported to be expressed in spindle cell neoplasia, and has been used to differentiate endometrial stromal sarcoma from leiomyoma and leiomyosarcoma. In the breast, myoepithelial cells express CD10, but there are few studies of the expression of CD10 in mammary fibroepithelial lesions. METHODS: Stromal CD10 expression was studied in 181 mammary phyllodes tumours (102 benign, 51 borderline malignant, and 28 frankly malignant) and 33 fibroadenomas using immunohistochemistry, to evaluate whether differences in expression correlated with the degree of malignancy. RESULTS: There was a progressive increase in the patients' age and tumour size, from fibroadenoma to phyllodes tumours with an increasing degree of malignancy (p < 0.001). Stromal CD10 expression was positive in one of 33 fibroadenomas, six of 102 benign phyllodes tumours, 16 of 51 borderline malignant phyllodes tumours, and 14 of 28 frankly malignant phyllodes tumours. The difference was significant (p < 0.001) and an increasing trend was established. Strong staining was seen in subepithelial areas with higher stromal cellularity and activity. Stromal CD10 expression had a high specificity (95%) for differentiating between benign lesions (fibroadenomas and benign phyllodes tumours) and malignant (borderline and frankly malignant) phyllodes tumours. CONCLUSIONS: CD10 may be a useful adjunct in assessing malignancy in mammary fibroepithelial lesions.
BACKGROUND/AIMS: CD10 (CALLA) has recently been reported to be expressed in spindle cell neoplasia, and has been used to differentiate endometrial stromal sarcoma from leiomyoma and leiomyosarcoma. In the breast, myoepithelial cells express CD10, but there are few studies of the expression of CD10 in mammary fibroepithelial lesions. METHODS: Stromal CD10 expression was studied in 181 mammary phyllodestumours (102 benign, 51 borderline malignant, and 28 frankly malignant) and 33 fibroadenomas using immunohistochemistry, to evaluate whether differences in expression correlated with the degree of malignancy. RESULTS: There was a progressive increase in the patients' age and tumour size, from fibroadenoma to phyllodes tumours with an increasing degree of malignancy (p < 0.001). Stromal CD10 expression was positive in one of 33 fibroadenomas, six of 102 benign phyllodestumours, 16 of 51 borderline malignant phyllodestumours, and 14 of 28 frankly malignant phyllodestumours. The difference was significant (p < 0.001) and an increasing trend was established. Strong staining was seen in subepithelial areas with higher stromal cellularity and activity. Stromal CD10 expression had a high specificity (95%) for differentiating between benign lesions (fibroadenomas and benign phyllodes tumours) and malignant (borderline and frankly malignant) phyllodestumours. CONCLUSIONS:CD10 may be a useful adjunct in assessing malignancy in mammary fibroepithelial lesions.
Authors: I P Shabalova; G J Chemeris; V D Ermilova; L M Rodionova; N A Pavlikova; K J Syrjänen Journal: Cytopathology Date: 1997-06 Impact factor: 2.073
Authors: V Kuenen-Boumeester; S C Henzen-Logmans; M M Timmermans; I L van Staveren; A van Geel; H J Peeterse; J Bonnema; E M Berns Journal: J Pathol Date: 1999-10 Impact factor: 7.996
Authors: Gary M K Tse; Thomas C Putti; Fred Y L Kung; Richard A Scolyer; Bonita K B Law; Tai-Shing Lau; C Soon Lee Journal: Mod Pathol Date: 2002-07 Impact factor: 7.842
Authors: G M K Tse; P-H Tan; P C W Lui; C B Gilks; C S P Poon; T K F Ma; B K B Law; W W M Lam Journal: J Clin Pathol Date: 2006-05-12 Impact factor: 3.411